Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Gross Profit: 2020-2024

Historic Gross Profit for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $1.3 million.

  • SAB Biotherapeutics' Gross Profit rose 44.52% to -$43,292 in Q3 2025 from the same period last year, while for Sep 2025 it was -$62,504, marking a year-over-year decrease of 104.36%. This contributed to the annual value of $1.3 million for FY2024, which is 40.94% down from last year.
  • SAB Biotherapeutics' Gross Profit amounted to $1.3 million in FY2024, which was down 40.94% from $2.2 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Gross Profit registered a high of $60.9 million during FY2021, and its lowest value of $1.3 million during FY2024.
  • Over the past 3 years, SAB Biotherapeutics' median Gross Profit value was $2.2 million (recorded in 2023), while the average stood at $9.2 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Gross Profit grew by 10.21% in 2021, and later crashed by 90.63% in 2023.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Gross Profit stood at $55.2 million in 2020, then rose by 10.21% to $60.9 million in 2021, then slumped by 60.73% to $23.9 million in 2022, then plummeted by 90.63% to $2.2 million in 2023, then crashed by 40.94% to $1.3 million in 2024.